非侵入性產前檢測市場、機會、成長動力、產業趨勢分析與預測，2024-2032

由於對早期和精確產前篩檢的需求激增，非侵入性產前檢測市場規模預計在 2024 年至 2032 年期間複合年成長率為 12.4%。

非侵入性產前檢測 (NIPT) 是一種安全可靠的方法，可用於識別胎兒的遺傳異常（例如唐氏症），同時對母親和孩子的風險最小。隨著人們對早期基因篩檢優勢的認知增強，對這些產品的需求也將增加。

新一代定序和生物資訊學的進步正在提高 NIPT 的準確性和效率，使其對準父母越來越有吸引力。隨著新興市場產前護理服務的普及和可支配收入的增加，產品採用率顯著上升，因為越來越多的人能夠負擔得起並積極尋求先進的產前篩檢服務。例如，2024年3月，BillionToOne在美國推出了一種新型產前基因測試“BabyPeek”

整個產業分為產品、技術、應用、最終用途和地區。

基於技術，PCR 領域的非侵入性產前檢測市場規模預計到 2032 年將產生可觀的收入，因為它在提高基因篩檢的準確性和可靠性方面發揮關鍵作用。 PCR 技術能夠熟練地放大和分析母體血液中發現的微量胎兒 DNA，從而以更高的靈敏度和特異性促進遺傳異常的檢測。

微缺失檢測應用領域的 NIPT 市場預計將在 2024 年至 2032 年期間出現強勁的複合年成長率。微缺失涉及染色體小片段的缺失，這可能導致各種遺傳性疾病。

亞太地區無創產前檢測產業規模將在 2024 年至 2032 年間大幅成長。此外，基因檢測的進步、更廣泛的醫療服務、遺傳性疾病盛行率的上升以及對及時、準確的產前護理的日益重視，都促進了該地區的市場發展。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 遺傳性疾病發生率高
    • 技術進步
    • 對早期和非侵入性診斷的需求不斷成長
    • 轉向非侵入性測試
  • 產業陷阱與挑戰
    • 道德考慮和測試成本
• 成長潛力分析
• 監管環境
• 報銷場景
• 技術景觀
• 未來市場趨勢
• 波特的分析
• PESTEL分析
• 流行病學情景
• 差距分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 耗材和試劑
• 儀器儀表
• 服務

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

• 主要趨勢
• NGS
• 聚合酶鍊式反應
• 遊離DNA
• 其他技術

第 7 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 三體檢測
• 微缺失檢測
• 性染色體非整倍體檢測
• 其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Agilent Technologies, Inc.
• BGI
• Centogene N.V.
• Eurofins LifeCodexx GmbH
• F. Hoffmann-La Roche Ltd.
• IGENOMIX
• Illumina, Inc.
• Labcorp
• MedGenome Labs Ltd.
• Myriad Women's Health, Inc.
• Natera, Inc.
• Pacific Biosciences
• PerkinElmer Inc.
• Progenity, Inc.
• Quest Diagnostics, Inc

Non-invasive prenatal testing market size is set to record a 12.4% CAGR during 2024-2032 propelled by a surging demand for early and precise prenatal screening.

Non-invasive prenatal testing (NIPT) stands out as a secure and dependable method for identifying genetic anomalies in fetuses, such as Down syndrome, all while posing minimal risks to both mother and child. As awareness about the advantages of early genetic screening amplifies, the demand for these products will also rise.

Advancements in next-generation sequencing and bioinformatics are bolstering the accuracy and efficiency of NIPT, rendering it increasingly appealing to expectant parents. With enhanced access to prenatal care and rising disposable incomes in emerging markets, there is a notable uptick in product adoption, as more individuals can afford and are actively seeking advanced prenatal screening services. For example, in March 2024, BillionToOne launched 'BabyPeek', a novel prenatal genetic test, in the U.S.

The overall industry is divided into product, technology, application, end-use, and region.

Based on technology, the non-invasive prenatal testing market size from the PCR segment is expected to generate notable revenue by 2032 due to its pivotal role in enhancing the accuracy and reliability of genetic screening. PCR technology adeptly amplifies and analyzes minute quantities of fetal DNA found in maternal blood, facilitating the detection of genetic anomalies with heightened sensitivity and specificity.

NIPT market from the microdeletion detection application segment is projected to observe a robust CAGR during 2024 - 2032. This is owing to its ability to identify subtle genetic abnormalities that are not always detected by traditional screening methods. Microdeletions involve the loss of small segments of chromosomes, which can lead to various genetic disorders.

Asia Pacific non-invasive prenatal testing industry size will grow substantially between 2024 and 2032. This growth is fueled by heightened awareness of advanced prenatal screening technologies, increasing disposable incomes, and an evolving healthcare infrastructure. Moreover, advancements in genetic testing, broader access to healthcare, a rising prevalence of genetic disorders, and a growing emphasis on timely and accurate prenatal care bolster the region's market development.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 High incidence rate of genetic disorders
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Growing demand for early and non-invasive diagnosis
    • 3.2.1.4 Shift toward non-invasive testing
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Ethical considerations and cost of the test
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Epidemiology scenario
• 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables and reagents
• 5.3 Instruments
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 NGS
• 6.3 PCR
• 6.4 cfDNA
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Trisomy detection
• 7.3 Microdeletion detection
• 7.4 Sex chromosome aneuploidy detection
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Agilent Technologies, Inc.
• 10.2 BGI
• 10.3 Centogene N.V.
• 10.4 Eurofins LifeCodexx GmbH
• 10.5 F. Hoffmann-La Roche Ltd.
• 10.6 IGENOMIX
• 10.7 Illumina, Inc.
• 10.8 Labcorp
• 10.9 MedGenome Labs Ltd.
• 10.10 Myriad Women's Health, Inc.
• 10.11 Natera, Inc.
• 10.12 Pacific Biosciences
• 10.13 PerkinElmer Inc.
• 10.14 Progenity, Inc.
• 10.15 Quest Diagnostics, Inc